GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2015

Summary

Gilead Sciences, Inc. reported strong financial results for the quarter ending June 30, 2015, driven by robust sales of its Hepatitis C (HCV) treatments, Harvoni and Sovaldi. Total revenues saw a significant increase of 27% year-over-year, reaching $8.2 billion, with product sales leading the growth. The company's net income also saw a substantial rise, indicating effective product performance and market penetration. Despite increased research and development (R&D) and selling, general, and administrative (SG&A) expenses, Gilead maintained healthy profit margins. The company also demonstrated strong cash flow generation from operations and managed its capital effectively, evidenced by substantial cash reserves and ongoing share repurchase programs. Gilead also initiated its first quarterly cash dividend, signaling confidence in its financial stability and commitment to returning value to shareholders.

Key Highlights

• 1Total revenues increased by 27% to $8.2 billion for the quarter ended June 30, 2015, compared to $6.5 billion in the prior year period.
• 2Product sales for the quarter rose to $8.1 billion, up 27% year-over-year, primarily driven by strong performance of HCV products Harvoni and Sovaldi.
• 3Net income attributable to Gilead increased to $4.5 billion, or $2.92 per diluted share, up from $3.7 billion, or $2.20 per diluted share, in the prior year period.
• 4Operating cash flow remained strong, generating $11.4 billion for the six months ended June 30, 2015.
• 5Cash, cash equivalents, and marketable securities stood at $14.7 billion as of June 30, 2015.
• 6The company initiated its first quarterly cash dividend of $0.43 per share, totaling $639 million, and continued its share repurchase program.
• 7R&D expenses increased by 40% to $818 million, and SG&A expenses increased by 32% to $812 million, reflecting continued investment in growth and pipeline.

Frequently Asked Questions